Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
- Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
- Renalys, Japan Kidney Association Join Hands to Develop Innovative Therapies
May 8, 2024
- Santen, Mitsubishi Tanabe to Copromote Alesion Eyelid Cream in Japan
May 8, 2024
- Astellas, Poseida Expand Collab in Off-the-Shelf Cell Therapies for Cancer
May 7, 2024
- Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
May 7, 2024
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
- Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
May 2, 2024
- Konica Minolta Divests Invicro in Precision Business Rejig
May 2, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Ono Picks Up Deciphera in US$2.4 Billion Deal to Extend Pipeline, Market Channels
May 1, 2024
- Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
- PeptiDream, Novartis Expand Peptide Discovery Collaboration
May 1, 2024
- Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
May 1, 2024
- Enhertu Beats Chemo in HR Positive, HER2 Low Breast Cancer
May 1, 2024
- PeptiDream to Start First-in-Human Trial for CAIX-Targeted Radiopeptide
April 30, 2024
- Sanofi Seeks COPD Nod for Dupixent in Japan
April 30, 2024
- Genmab Files ADC Tisotumab Vedotin for Cervical Cancer in Japan
April 30, 2024
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…